Patent intelligence · US
US 11014931
3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine as an ion channel modulator
3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine as an ion channel modulator
Patent details — US 11014931
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 25, 2021
- Expiration
- May 20, 2041
- Applicant
- PRAXIS PRECISION MEDICINES, INC.
- Claims
- 18
- CPC classes
- A61K, A61K45/06, A61P, A61P23/00
Quick answer
US 11014931 (3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine as an ion channel modulator) is held by PRAXIS PRECISION MEDICINES, INC.. Status: granted. Granted May 25, 2021. Expires May 20, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PRAXIS PRECISION MEDICINES, INC.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K45/06, A61P, A61P23/00, A61P25/08, A61P29/00
More from PRAXIS PRECISION MEDICINES, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12404297
Salts and crystal forms of GABA-A positive allosteric modulator
granted -
US 12325711
3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-α]pyrazine as an ion channel modulator
granted -
US 12259378
Dynamic clamps and methods of use thereof
granted -
US 12145939
Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
granted -
US 12077502
Formulations of T-type calcium channel modulators and methods of use thereof
granted -
US 11918571
Compounds and their methods of use
granted -
US 11919836
Prodrugs of fencamfamine
granted -
US 11866439
Ion channel modulators
granted
Frequently asked questions
What is US patent 11014931?
US 11014931 (3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine as an ion channel modulator) is held by PRAXIS PRECISION MEDICINES, INC.. Status: granted. Granted May 25, 2021. Expires May 20, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11014931?
PRAXIS PRECISION MEDICINES, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 35 pharmaceutical patents for this assignee.
When does US 11014931 expire?
Our index shows an expiration date of May 20, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.